GLP-1 Meds Reduce Risk of Various Ocular Complications in Non-diabetic Patients

This study suggests potential protective ophthalmic effects of anti-obesity GLP-1 therapies for several ophthalmic conditions in non-diabetic patients. Photo: Novo Nordisk. Click image to enlarge. While GLP-1 receptor agonists like semaglutide and tirzepatide are now widely used for weight loss, research to understand their impact on eye health has largely been limited to diabetic patients. A study presented recently at ARVO 2026 analyzed the incidence of glaucoma, macular and ophthalmic diseases over a four-year period among non-diabetic adults prescribed GLP-1 drugs and found these medications provide a variety of protective signals.A retrospective cohort study was conducted using the TriNetX US Collaborative Network. Non-diabetic adults with BMI ≥27kg/m2 and one or more eyecare encounters between 2021 and 2025 were included, with 31,063 patients included in each cohort. The exposure group received semaglutide, tirzepatide or liraglutide for weight loss; comparators had no GLP-1 prescriptions. Propensity score matching incorporated demographics, comorbidities, ocular history and medications. Primary outcomes were incident glaucoma suspect (GS), primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG), dry and wet AMD, cystoid macular edema (CME) and non-arteritic ischemic optic neuropathy (NAION).GLP-1 agonist use was associated with moderate reduction in risk for GS, CME and (surprisingly) NAION, strong reduction for POAG and PACG and robust reduction for dry and wet AMD. The exact findings are as follows: GS incidence was 1.5% vs 2.82%, POAG was 0.39% vs 1.01%, PACG was 0.06% vs 0.15%, dry AMD was 0.26% vs 0.93%, CME was 0.51% vs 1.05%, wet AMD was 0.09% vs 0.44% and NAION was 0.08% vs 0.136%. The ARVO abstract did not comment on the NAION result, which runs counter to several previous studies showing an elevated risk.This data suggests potential protective ophthalmic effects of anti-obesity GLP-1 therapies for several ophthalmic conditions in non-diabetic patients that warrant further mechanistic and longitudinal investigation.Original abstract ©2026 Association for Research in Vision and Ophthalmology.Click here for the source. Visher T, Agarwal R, Zhang A, et al. Glaucoma, ocular and optic nerve disease in non-diabetic adults receiving GLP-1 agonists for weight loss: a propensity-matched cohort study. ARVO 2026 annual meeting. This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.